FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1971969583> ?p ?o ?g. }

• W1971969583 endingPage "e30353" @default.
• W1971969583 startingPage "e30353" @default.
• W1971969583 abstract "Vandetanib is a multikinase inhibitor that is under assessment for the treatment of various cancers. QTc interval prolongation is one of the major adverse effects of this drug, but the reported incidence varies substantially among clinical trials. We performed a systematic review and meta-analysis to obtain a better understanding in the risk of QTc interval prolongation among cancer patients administered vandetanib.Eligible studies were phase II and III prospective clinical trials that involved cancer patients who were prescribed vandetanib 300 mg/d and that included data on QTc interval prolongation. The overall incidence and risk of QTc interval prolongation were calculated using random-effects or fixed-effects models, depending on the heterogeneity of the included studies. Nine trials with 2,188 patients were included for the meta-analysis. The overall incidence of all-grade and high-grade QTc interval prolongation was 16.4% (95% CI, 8.1-30.4%) and 3.7% (8.1-30.4%), respectively, among non-thyroid cancer patients, and 18.0% (10.7-28.6%) and 12.0% (4.5-28.0%), respectively, among thyroid cancer patients. Patients with thyroid cancer who had longer treatment duration also had a higher incidence of high-grade events, with a relative risk of 3.24 (1.57-6.71), than patients who had non-thyroid cancer. Vandetanib was associated with a significantly increased risk of all-grade QTc interval prolongation with overall Peto odds ratios of 7.26 (4.36-12.09) and 5.70 (3.09-10.53) among patients with non-thyroid cancer and thyroid cancer, respectively, compared to the controls.Treatment with vandetanib is associated with a significant increase in the overall incidence and risk of QTc interval prolongation. Different cancer types and treatment durations may affect the risk of developing high-grade QTc interval prolongation." @default.
• W1971969583 created "2016-06-24" @default.
• W1971969583 creator A5007671743 @default.
• W1971969583 creator A5014401669 @default.
• W1971969583 creator A5019491306 @default.
• W1971969583 creator A5023276519 @default.
• W1971969583 creator A5027674411 @default.
• W1971969583 creator A5039520635 @default.
• W1971969583 creator A5041358763 @default.
• W1971969583 creator A5043014407 @default.
• W1971969583 creator A5044988120 @default.
• W1971969583 creator A5089455733 @default.
• W1971969583 date "2012-02-17" @default.
• W1971969583 modified "2023-10-11" @default.
• W1971969583 title "Incidence and Risk of QTc Interval Prolongation among Cancer Patients Treated with Vandetanib: A Systematic Review and Meta-analysis" @default.
• W1971969583 cites W1480729244 @default.
• W1971969583 cites W1485216956 @default.
• W1971969583 cites W1964435302 @default.
• W1971969583 cites W1986215651 @default.
• W1971969583 cites W1996802734 @default.
• W1971969583 cites W1998482951 @default.
• W1971969583 cites W2017493472 @default.
• W1971969583 cites W2023375628 @default.
• W1971969583 cites W2038693293 @default.
• W1971969583 cites W2054195660 @default.
• W1971969583 cites W2056918035 @default.
• W1971969583 cites W2061415456 @default.
• W1971969583 cites W2066823769 @default.
• W1971969583 cites W2074599212 @default.
• W1971969583 cites W2093070825 @default.
• W1971969583 cites W2102590541 @default.
• W1971969583 cites W2104374675 @default.
• W1971969583 cites W2107666024 @default.
• W1971969583 cites W2109833554 @default.
• W1971969583 cites W2111273013 @default.
• W1971969583 cites W2114940128 @default.
• W1971969583 cites W2115078104 @default.
• W1971969583 cites W2118559000 @default.
• W1971969583 cites W2124464299 @default.
• W1971969583 cites W2125916043 @default.
• W1971969583 cites W2129638180 @default.
• W1971969583 cites W2133367456 @default.
• W1971969583 cites W2135703067 @default.
• W1971969583 cites W2156400205 @default.
• W1971969583 cites W2157823046 @default.
• W1971969583 cites W2322887621 @default.
• W1971969583 cites W3022523435 @default.
• W1971969583 cites W4245640520 @default.
• W1971969583 doi "https://doi.org/10.1371/journal.pone.0030353" @default.
• W1971969583 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3281826" @default.
• W1971969583 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22363427" @default.
• W1971969583 hasPublicationYear "2012" @default.
• W1971969583 type Work @default.
• W1971969583 sameAs 1971969583 @default.
• W1971969583 citedByCount "80" @default.
• W1971969583 countsByYear W19719695832012 @default.
• W1971969583 countsByYear W19719695832013 @default.
• W1971969583 countsByYear W19719695832014 @default.
• W1971969583 countsByYear W19719695832015 @default.
• W1971969583 countsByYear W19719695832016 @default.
• W1971969583 countsByYear W19719695832017 @default.
• W1971969583 countsByYear W19719695832018 @default.
• W1971969583 countsByYear W19719695832019 @default.
• W1971969583 countsByYear W19719695832020 @default.
• W1971969583 countsByYear W19719695832021 @default.
• W1971969583 countsByYear W19719695832022 @default.
• W1971969583 countsByYear W19719695832023 @default.
• W1971969583 crossrefType "journal-article" @default.
• W1971969583 hasAuthorship W1971969583A5007671743 @default.
• W1971969583 hasAuthorship W1971969583A5014401669 @default.
• W1971969583 hasAuthorship W1971969583A5019491306 @default.
• W1971969583 hasAuthorship W1971969583A5023276519 @default.
• W1971969583 hasAuthorship W1971969583A5027674411 @default.
• W1971969583 hasAuthorship W1971969583A5039520635 @default.
• W1971969583 hasAuthorship W1971969583A5041358763 @default.
• W1971969583 hasAuthorship W1971969583A5043014407 @default.
• W1971969583 hasAuthorship W1971969583A5044988120 @default.
• W1971969583 hasAuthorship W1971969583A5089455733 @default.
• W1971969583 hasBestOaLocation W19719695831 @default.
• W1971969583 hasConcept C118441451 @default.
• W1971969583 hasConcept C120665830 @default.
• W1971969583 hasConcept C121332964 @default.
• W1971969583 hasConcept C121608353 @default.
• W1971969583 hasConcept C126322002 @default.
• W1971969583 hasConcept C143998085 @default.
• W1971969583 hasConcept C156957248 @default.
• W1971969583 hasConcept C2777672339 @default.
• W1971969583 hasConcept C2778019345 @default.
• W1971969583 hasConcept C2778695046 @default.
• W1971969583 hasConcept C2779761222 @default.
• W1971969583 hasConcept C2780333294 @default.
• W1971969583 hasConcept C44249647 @default.
• W1971969583 hasConcept C61511704 @default.
• W1971969583 hasConcept C71924100 @default.
• W1971969583 hasConcept C95190672 @default.
• W1971969583 hasConceptScore W1971969583C118441451 @default.
• W1971969583 hasConceptScore W1971969583C120665830 @default.
• W1971969583 hasConceptScore W1971969583C121332964 @default.

• next